Monopar Therapeutics Inc. Profile Avatar - Palmy Investing

Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet…

Biotechnology
US, Wilmette [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of MNPR's Analysis
CIK: 1645469 CUSIP: 61023L108 ISIN: US61023L1089 LEI: - UEI: -
Secondary Listings
MNPR has no secondary listings inside our databases.